
Arpita Desai, MD, and Andre Kydd, MD, walk through the LITESPARK-022 enrollment criteria and the 7% disease-free survival benefit at two years.

Arpita Desai, MD, and Andre Kydd, MD, walk through the LITESPARK-022 enrollment criteria and the 7% disease-free survival benefit at two years.

Desai and Kydd discuss LITESPARK-022's immature overall survival signal (HR 0.78) and the 22% increase in grade 3+ adverse events with belzutifan.

Desai and Kydd on managing anemia and hypoxia from belzutifan, patient risk-benefit conversations, and sequencing considerations in high-risk adjuvant RCC.